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Abstract
Background: Less than 30% of malignant gliomas respond to adjuvant chemotherapy. Here, we have asked
whether variations in the constitutive expression of early-growth response factor 1 (EGR-1) predicted acute
cytotoxicity and clonogenic cell death in vitro, induced by six different chemotherapics.
Materials and methods: Cytotoxicity assays were performed on cells derived from fresh tumor explants of 18
human cases of malignant glioma. In addition to EGR-1, tumor cultures were investigated for genetic alterations
and the expression of cancer regulating factors, related to the p53 pathway.
Results: We found that sensitivity to cisplatin correlates significantly with levels of EGR-1 expression in tumors with
wild-type p53/INK4a/p16 status.
Conclusion: Increased knowledge of the mechanisms regulating EGR-1 expression in wild-type p53/INK4a/p16
cases of glioma may help in the design of new chemotherapeutic strategies for these tumors.
Introduction
Malignant brain tumors of glial origin are highly inva-
sive and poorly sensitive to anti-proliferative drugs, with
only 20-30% of patients responding to chemotherapy.
The biological basis of drug resistance in these tumors
is complex, being dependent to some extent on the
genetic make-up of the tumor. The prognostic value of
molecular markers has been investigated either retro-
spectively, in patients treated with standard therapy, or
in tumor cells cultured in vitro and exposed to different
chemotherapics, but no clear results have emerged [1].
The role of p53 gene status [2], the presence of dele-
tions in the INK4a/INK4b locus coding for the tumor
suppressors and cell cycle regulators p16, p15 and
p14ARF [3], the MGMT (O
6-methylguanine DNA
methyltransferase) levels [4] and the levels of expression
for several players and regulators of apoptosis [5] were
all studied to predict the response of the tumor to
specific drugs. The rationale of these studies was that
tumor cells react to the genotoxic insult by p53-depen-
dent cell cycle arrest, or by undergoing apoptosis [6].
However, from these studies none of these factors,
except MGMT, emerged as a major determinant of che-
moresistance [7].
Many genes are found to be defective and others are
deregulated in gliomas [8]. We have recently found that
EGR-1 expression is downregulated in malignant glio-
mas [9]. EGR-1 encodes a nuclear transcription factor
responsible for the regulation of cell differentiation and
proliferation of several cell lineages, in response to
external stimuli. By regulating, either positively or nega-
tively, target genes such as TGF-b, cyclin D1, c-jun,
PTEN, p53 and p21, EGR-1 decreases cell proliferation,
carrying out tumor suppressive functions in several
tumor types including gliomas [10,11]. In addition, some
authors have found that its expression is associated with
enhanced patient survival [12,13]. We also observed that
EGR-1 is less expressed in tumors and tumor-derived
primary cell lines carrying wild type copies of p53 gene
compared to those carrying p53 mutated copies [14].
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tion of p53, since it acts as an upstream regulator of the
p53 tumor suppressor pathway [15]. In turn, overexpres-
sion of mutant p53 activates EGR-1 expression which is
implicated in the enhanced resistance to genotoxic
stress, at least in human prostate and lung cancer cell
lines [16]. The interplay between EGR-1 and p53 in
gliomas may therefore be of high relevance to both
tumor progression and drug resistance. Cisplatin is one
of the most effective chemotherapeutic agents to date
used for the treatment of many malignancies, including
glioma [17]. Cisplatin causes tumor cell death by direct
DNA damage and by generating reactive oxygen inter-
mediates. Recent findings have suggested that these two
factors may be responsible for activating the EGR-1 pro-
moter. It was concluded that EGR-1 promoter can be
induced by cisplatin [18]. In addition, pre-clinical studies
have shown that cisplatin may be synergic with temozo-
lomide, an oral alkylating agent, which is now widely
used in the standard treatment of newly diagnosed and
recurrent malignant gliomas [19,20]. In view of these
results, we have asked the question whether EGR-1 has
any role in chemoresistance to cisplatin or other drugs
in glioma primary cells in vitro, and if this is related to
the p53 status of the tumor or to other genes whose
activity is required for the proper cytotoxic response. To
this end, we have examined the response of freshly
derived primary cell lines of malignant glioma, each
established in our laboratory from a different donor, to
cisplatin and five other cytotoxic drugs of relevant use.
We concluded that the levels of EGR-1 protein in each
cell line from wild-type cases of glioma strongly corre-
late with sensitivity to cisplatin.
Results
Primary cell lines differ in their response to anti-tumor
drugs
Eighteen glioma primary cell lines were each challenged
with six cytotoxic drugs, namely vincristine, cisplatin,
camptothecin, mitomycin C, etoposide (VP16), and dox-
orubicin, in the acute cytotoxicity assay (Figure 1). In
the upper left quadrant, cell lines are ordered according
to the concentration of vincristine needed to reduce by
50% (EC50) the number of living cells after three days
of exposure, compared to the untreated control. Some
of the cell lines (CNT-1, FLS-10, BMR-76, and FCN-9)
were completely refractory. Therefore the EC50 could
not be calculated. In such cases we provided the cell
line with a EC50 value corresponding to the maximal
administered dose which, in the case of vincristine, was
100 μg/ml. In the other quadrants cell lines are shown
in the same order as for vincristine. Two cell lines
(CDR-97, CNT-1) were resistant to camptothecin, one
(BUBU-0) to etoposide, and one (CRL-8) to doxorubicin.
As above, in these cases the assumed values of EC50
were 15, 300, and 25 μg/ml, respectively.
The EC50 values corresponding to the drug concentra-
t i o nn e e d e dt ol o w e rb y5 0 %t h ec l o n o g e n i ca c t i v i t yo f
the cell lines are shown in Figure 2. Cell lines and EC50
values are presented with the same modality as in Figure
1. GSS-98 and CDR-97, since they are not clonogenic in
vitro, could not be examined by the clonogenic assay and
are not shown on the figure. According to the clonogenic
assay, BMR-76 is resistant to vincristine, BUBU-0 to cis-
platin, CRL-8 to camptothecin, and PRZ-11 to mitomy-
cin C. In these cases we assumed as EC50 the values of
2.5, 5, 30, and 5 μg/ml, respectively. Most cell lines show
wide ranges of response and different patterns of sensitiv-
ity. As an example, we show four representative cases of
cell lines with different levels of sensitivity to cisplatin,
translating into more (PRZ-11, MZC-12) or less (BMR-
76, FCN-9) variable rates of survival when challenged
with different drug amounts (Figure 3).
For each drug tested the mean, median, minimum,
and maximum EC50 values are shown in Table 1
according to the acute cytotoxicity or the clonogenic
assay. The ratio between the minimum and the maxi-
mum EC50 values for each drug is also reported. Except
for doxorubicin, the EC50 values provided by the clono-
genic assay range within a wider interval.
Primary cell lines are more sensitive to cisplatin when the
frequency of EGR-1 positive cells in the tumor is lower
All eighteen primary cell cultures have been investigated
in parallel for EGR-1 expression by immunofluorescence
(IF), immunocytochemistry (IK) (Figure 4A,B) and wes-
tern blot (WB). EGR-1 IF and IK positive cell lines are
quantitated as percent positive cells, and are partially
correlated to each other (R = .475, p = .0453). More sig-
nificant is the correlation between EGR-1 IK (Figure 4A,
B) and WB values (R = .703, p = .0007) [14]. For the
further analysis, we have taken the values from immu-
nocytochemistry as representative of EGR-1 expression.
Percent IK positive cells range from 5% in the case of
PMG-71 to 83% for CRL-8 (see below in Figure 4C).
We then examined the correlation between the fraction
of EGR-1 positive cells and the EC50 values seen for
each drug. EGR-1 expression correlates significantly (R
= .744, p = .0009) with sensitivity to cisplatin measured
by the clonogenic assay (Figure 4C).
EGR-1 expression, mutations in oncosoppressive genes
and drug cytotoxicity
Six out of 18 cell lines have mutations in the p53 gene or
in the p16/INK4a/ARF gene complex. None has amplified
copies of mdm2 gene. Thus, CRL-8 has a homozygous
mutation at codon 216 (Val®Met), FCN-9 at codon 224
(ag®aa), MZC-12 and BUBU-0 at codon 248 (Arg®Glu)
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Page 2 of 10of p53 gene. FLS-10 and GSS-98 present a homozygous
deletion at the p16/INK4a/ARF locus [14]. Thus, concern-
ing the relationship between drug sensitivity and EGR-1
expression, we asked the question whether the presence of
the above mutations in these cell lines may affect their
response. After dividing the cell lines into two groups,
mutated and not-mutated, we found that sensitivity to cis-
platin correlates significantly with the percentage of EGR-
1 positive cells only in cell lines without mutations (R =
.696, p = .0173). In addition to cisplatin we found that the
levels of EGR-1 expression in these cell lines also corre-
lated significantly with sensitivity to Mitomycin C, as seen
by the acute cytotoxicity assay (R = .588, p = .0444). The
mean value of EC50 to each drug was then calculated for
the groups of mutated and not-mutated cell lines, and
compared with each other (Table 2). Differences between
mutated (column D) and not-mutated (column C) cell
lines were found for the response to camptothecin (1.127
vs. 0.025, p = 0,007), mitomycin C (0.075 vs. 0.002, p =
0.026) and etoposide (1.312 vs. 9.410, p = 0.052), all cases
measured by the clonogenic assay. Mutated cell lines have
higher values of EGR-1 (54.66% vs. 35.33%). In addition,
we divided the group of not-mutated cell lines into two
further subgroups of six cell lines each, with low and high
EGR-1 values, respectively, and compared their mean
EC50 (Table 2). The two not-mutated groups with lower
and higher EGR-1 differed significantly in their mean
EC50 for vincristine (0.069 vs. 0.664; p = 0.044) and cispla-
tin (0.427 vs. 1.960; p = 0.034), measured by the clono-
genic assay, and for mitomycin C (3.218 vs. 0.413; p =
0,040) by the acute citotoxicity assay.
Finally, we elaborated an index for ranking the cell
lines according to their sensitivity by integrating their
responses into an overall cumulative score based on the
results obtained with the acute cytotoxic assay and the
clonogenic assay, respectively. The clonogenic ranking
index (Figure 4D) correlates significantly with the values
of EGR-1 expressed in the not-mutated cell lines (R =
0.872, p = 0.0002).
Tumorigenic expression and drug sensitivity in glioma
primary cell lines
We investigated the expression of other tumor-related
products, in addition to EGR-1, which might be
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Figure 1 Distribution of EC50 (μg/ml) index calculated for six anti-cancer therapeutic drugs in primary cell lines of human glioma.
Drug responses were evaluated with the acute cytotoxicity assay.
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Page 3 of 10influencing the response of the tumor cells to the anti-
neoplastic treatment. We calculated by immunofluores-
cence the percentage of cells carrying the expression of
MDM2, GFAP, and p21, and by western blot the pro-
duction of fibronectin, Bcl-2, Bcl-xL, Bax (Figure 5) and
TGF-b. We then assessed whether there was an associa-
tion between drug sensitivity and these other para-
meters. We found that the percentage of MDM2
positive cells correlates significantly with the response to
doxorubicin in the acute assay (R = .619, p = .0062) and
to vincristine in the clonogenic assay (R = .504, p =
.0466), and that the production of TGF-b correlates sig-
nificantly with the response to etoposide in the acute
assay (R = .517, p = .0336). These correlations refer to
the whole group of cell lines. As to the subgroup of cell
lines not carrying mutations in the p53 gene or the p16/
INK4a/ARF gene complex, we again found statistically
significant correlations between the percentage of
MDM2 positive cells and the response to doxorubicin
(R = .79 with p = .0022, and R = .765 with p = .0061)
and to vincristine (R = .569 with p = .0535, and R =
.644 with p = .0325) in the acute cytotoxicity and the
clonogenic assay, respectively, between the response to
VP16 and the production of both TGF-b (R = .609, p =
.0357) and Bax (R = .764, p = .0457), the production of
fibronectin and the response to cisplatin (R = .826, p =
.0116) and to camptothecin (R = .732, p = .0389) in the
clonogenic assay and, finally, between the percentage of
GFAP positive cells and the response to Mitomycin C in
the clonogenic assay (R = .896, p = .0002). This last
association has clearly been the most significant.
Discussion
Resistance to anti-neoplastic drugs is certainly one of
the most important factors that limits the progress of
current therapy for cancer. Chemoresistance in glioma
is based on a complex network of multiple pathophysio-
logical mechanisms such as altered functioning of mem-
brane pumps, poor tumor perfusion or insufficient
blood vessel supply, to cite only a few [21,22]. At mole-
cular level, one of the most investigated factors is repre-
sented by p53. Although p53 is a crucial apoptotic cell
Vincristine Cisplatin Camptothecin
Mitomycin C Etoposide Doxorubicin
Figure 2 Distribution of EC50 (μg/ml) index calculated for six anti-cancer therapeutic drugs in primary cell lines of human glioma.
Drug responses were evaluated with the clonogenic assay.
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Page 4 of 10death mediator in cancer cells following genotoxic
stress, its direct role in chemosensitivity of gliomas is
still controversial. In fact, studies in vitro of the p53
genetic or functional status of glioma cell lines failed to
predict in either acute cytotoxicity or clonogenic cell
death assays the response to anticancer drugs [23]. It
was concluded by many that the role of p53 in tumor
therapy is complex, and its status cannot be taken as a
predictive tool. Most of the well characterized estab-
lished cell lines from glioma have run through countless
passages in vitro. As a result, they must have
accumulated both chromosomal and gene mutations,
aside from the genetic alterations present in the tumor
from which they were derived. Secondly, they all have
mutated copies of p53, p16,o rmdm2 genes and thus
have an altered p53 pathway. At variance with these
reports, in our study we worked with freshly derived pri-
mary cell lines, which replicated for a very limited num-
ber of passages. Only 6 cell lines out of 18 have
mutations occurring at the p53 or p16 genes, and none
had mutations at the mdm2 gene locus. We could there-
fore compare our assay results between p53 mutated
and not-mutated cell lines. We focused on the question
whether EGR-1 expression might be related to chemo-
sensitivity of the tumor cells in vitro. EGR-1 has multi-
ple roles that might affect cell sensitivity to antiblastic
drugs. In fact, EGR-1 is responsible for regulating cell
proliferation and the response to several types of stress
stimuli, including the apoptotic response. For these
properties and for being deregulated in human gliomas,
as in other tumors, we sought to look for correlations
between the levels of EGR-1 expression in our cell lines
and their sensitivity to genotoxic anticancer drugs. We
found that EGR-1 expression levels did in fact correlate
with response to cisplatin: the lower is EGR-1 expressed,
the higher is the cytotoxic response. In conclusion,
EGR-1 emerged as a predictor of chemoresistance for
cisplatin. We found that EGR-1 levels correlate signifi-
cantly with sensitivity to cisplatin both in cell lines with-
o u tm u t a t i o n si nt h ep 5 3p a t h w a ya n di nt h ew h o l e
group, and that this applies also to several other drugs,
though to a lesser extent. The same is not true for the
six cell lines with mutated p53. These results are in
agreement with the general view that mutations affect-
ing the p53 response pathway act unfavorably by accel-
erating the progression of the disease and possibly by
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Figure 3 Survival rates of four primary cell lines treated with
different amounts of cisplatin. Rates are referred to day 3 after
treatment in the acute cytotoxicity assay.
Table 1 Summary of cytotoxicity assay results
Clonogenic
assay
Acute
cytotoxic
assay
Count Mean Median Minimum Maximum EC50
ratio
Vincristine 16 0.264 0.082 0.0002 2.5 12,500
Cisplatin 16 1.330 0.760 0.020 5.0 250
Camptothecin 16 0.783 0.160 0.001 5.0 5,000
Mitomycin C 16 0.053 0.007 0.00004 0.450 11,250
Etoposide 16 3.843 1.333 0.016 30 1,875
Doxorubicin 16 0.028 0.018 0.001 0.079 79
Vincristine 18 29.038 5.000 0.080 100 1,250
Cisplatin 18 12.333 4.750 2.600 45 17.3
Camptothecin 18 2.552 0.395 0.040 15 375
Mitomicin C 18 1.782 0.550 0.050 7 140
Etoposide 18 62.111 46.500 14.000 300 21.4
Doxorubicin 18 3.253 0.535 0.150 25 166.7
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Page 5 of 10affecting the cytotoxic response to drugs. That tumors
are more sensitive to the anti-neoplastic action of drugs
when EGR-1 is less expressed is compatible with the
protective properties of EGR-1 as anti-stress agent, and
with the fact that EGR-1 down-regulation is likely to be
a prerequisite for the growth of tumors harbouring
intact copies of p53 gene. We also found a correlation
between MDM2 expression and drug sensitivity. In fact,
both the sensitivity to doxorubicin and to vincristine
increase their correlation with the percent of MDM2
positive cells when they are assessed in cell lines which
carry only wild-type copies of the p53 gene, from .62 to
.79 in the case of doxorubicin assessed with the acute
cytotoxicity assay, and from .50 to .64 for vincristine
assessed with the clonogenic assay. We interpreted these
results according to the view that when p53 is func-
tional, an increase in the fraction of MDM2 positive
cells should parallel an increase in the fraction of cells
where p53 becomes inactive. This is in contrast with
past evidence that there is no role for the levels of p21
or MDM2 proteins as a predictor of response to che-
motherapeutics in glioma cell lines [24,25].
Conclusion
The results of chemotherapy in gliomas are largely dis-
appointing. In fact, even temozolomide which is the
gold standard today for first-line therapy of glioblasto-
mas, is ineffective in resistant primary gliomas and in
most of the recurrent malignant cases, for which at pre-
sent there are no chemotherapeutic regimens. A better
knowledge of the molecular markers for chemosensitiv-
ity could help us to identify the cases which are sensitive
to the most used chemotherapeutics. Our results pro-
vide new preliminary evidence for the role of EGR-1 as
a molecular factor involved in the chemosensitivity of
glioma. Several authors have already indicated that resis-
tant and recurrent gliomas can be alternatively treated
with cisplatinum in combination with other drugs
Figure 4 EGR-1 expression by immunoistochemistry and response to anticancer drugs in primary cell lines of glioma.A )B M R - 7 6
primary cell line showing EGR-1 positive cells with different levels of positivity detected by an anti-EGR-1 polyclonal antibody. B) FLS-10, a
mostly negative primary cell line. C) Relationship between the percentage of EGR-1 positive cells measured by immunoistochemistry and the
EC50 response to cisplatin, measured with the clonogenic assay. D) Relationship between the clonogenic index and the percentage of EGR-1
positive cells measured by immunocytochemistry, in primary cell lines of human glioma carrying wild type copies of p53, p16/INK4a and MDM2
genes. This index is a global measure of the sensitivity to the six anticancer drugs measured with the clonogenic assay.
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Page 6 of 10Table 2 Comparison of EC50 mean values between mutated and not-mutated cell lines
Cell lines without mutations Cell lines with mutations
ABC D
Lower
IK EGR-1
n=6
Higher
IK EGR-1
n=6
Total
n=1 2
Total
n=6
X
a = 22.33 X
a = 48.33 X
a = 35.33 X
a = 54.66
Vincristine C
b 0.069 0.664 0.339 0.098
A
c 27.31 21.21 24.27 38.58
Cisplatin C 0.427 1.960 1.124 1.784
A 15.73 16.83 16.3 4.433
Camptothecin C 0.472 1.914 1.127 0.025
A 2.783 2.992 2.887 1.881
Mitomycin C C 0.089 0.09 0.075 0.002
A 3.218 0.413 1.82 1.715
Etoposide C 0.819 1.904 1.312 9.410
A 50.16 50.66 50.41 85.50
Doxorubicin C 0.021 0.035 0.027 0.028
A 0.758 4.180 2.47 4.820
EC50 values were compared between column A and B, and between column C and D.
Statistically different EC50 values are in bold (see inside text).
X
a = IK EGR-1 mean value.
b = clonogenic assay,
c = acute cytotoxicity assay.
Figure 5 Western blot of BCL-2, Bax and BCL-X in glioma derived primary cell cultures. b-Actin was used as loading control.
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Page 7 of 10[19,26]. Validation of these observations on a larger
scale, together with functional experiments, could pave
the way toward the elucidation of new molecular aspects
of pathophysiology of drug resistance and the definition
of a sensitive tool for the prediction of a successful
therapy.
Materials and methods
Glioma primary cell cultures
The research protocol was drafted in accordance with
the Declaration of Helsinki, reviewed and approved by
an institutional board. Written informed consent for
research use of tumor tissue was obtained from each
patient prior to surgery. Primary cell lines were estab-
lished from anaplastic astrocytoma or glioblastoma mul-
tiforme tissue obtained ats u r g e r ya n dd i a g n o s e d
according to the W.H.O. classification. Cells were cul-
tured in Dulbecco’s modified Eagle medium containing
10% fetal calf serum and 2% glutamine. We used fresh
cells collected from passage 3 to 8, or cells preserved in
liquid nitrogen from earlier passages. Several cell lines
have been reported in a previous paper [14].
Anti-tumor drugs
Six cancer therapeutic drugs have been tested in our
assays: a mitotic inhibitor, vincristine; two cross-linkers
of DNA, cisplatin and mitomycin C; an anthracyclin
antibiotic which intercalates DNA, doxorubicin; an inhi-
bitor of the DNA enzyme topoisomerase I, camptothe-
cin; and an inhibitor of the enzyme topoisomerase II,
etoposide. They were all purchased from Sigma Inc. (St.
Louis, MO, USA). Drugs were dissolved at 100 times
the final concentration tested, and sterilized by filtration
before use. Stock drugs solutions were made in absolute
ethyl alcohol (vincristine), in 10 mM dimethylsulfoxide
(mitomycin C, cisplatin, camptothecin, etoposide), or in
water (doxorubicin). Vincristine and doxorubicin were
each time freshly prepared, cisplatin was stored at room
temperature, all the others at -20 C.
Drug sensitivity
For the acute cytotoxicity assay, the glioma cells were
seeded at 5 × 10
3 cells per well in 96-well plates, allowed
to attach for 24 h and subsequently exposed to drugs for
72 h in triplicate wells. Cell survival was determined using
a colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay [27]. Fifty μl of 5 mg/
μl MTT was added to each well and incubated for 4 h at
37°C. The absorption was read at 540 nm using an auto-
mated microplate reader. For the clonogenic assay, cells
were seeded at 0.5 × 10
3 cells per well in 96-well plates,
allowed to attach for 48 h, exposed to the drugs for 24 h,
washed, and allowed to grow for 2 to 3 weeks in drug-free
medium. The control wells were carefully monitored not
to reach confluence during these assays. Growth was mea-
sured by crystal violet assay [27]. The colonies were
stained, and the dye was subsequently released by citrate
buffer for quantification in an ELISA reader. Results were
given as the drug concentration dose which affected cell
growth by 50% compared to untreated cultures (EC50, μg/
ml). The EC50 value is obtained by linear interpolation of
growth values of cells following treatment with a mini-
mum of four different doses.
Western Blot Analysis
Bcl-2, Bcl-xl and Bax, were all detected in 100 μgo f
protein from whole cell extracts, according to the proce-
dure described in [9,10]and actin was used as loading
control. Protein concentration was estimated using
BioRad assay kit. Primary and secondary antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
Ca USA). Relative measures of protein expression were
obtained through densitometric analysis of Western blot
chemiluminescent bands using the public domain NIH
I m a g es o f t w a r e( d e v e l o p e da tt h eU . S .N a t i o n a lI n s t i -
tutes of Health) and normalizing with respect to the
actin content of each sample.
Immunofluorescence and immunocytochemistry
For EGR-1, we stained the cells with the same primary
antibody used in western blot experiments. Immuno-
fluorescence and immunocytochemistry were performed
on cells fixed in 4% fresh paraformaldehyde. Cells were
also stained with a mouse monoclonal antibody against
GFAP (Sigma), and mouse monoclonal antibodies
against p21 and MDM2 (Pharmingen Corporation, San
Diego CA, USA). Immunocytochemistry was performed
using avidin-biotin-peroxidase (ABC Universal kit, Vec-
tor Laboratories, Burlingame CA, USA) following the
manufacturer’s protocol. Values are expressed as percen-
tage of positive cells stained.
Analysis of p53 mutations
p53 mutations in exons 5 to 9 were sequenced as
described in [9,25]. Sequencing was performed using a
Big Dye terminator DNA sequencing kit with the ABI
PRISM 377 DNA Sequencer (PE Applied Biosystems
Inc., Foster City CA, USA), according to the manufac-
turer’s instructions.
Assessment of p16 and MDM2 status
Analysis of allele dosage for MDM2 and loss of hetero-
zygosity at the p16/INK4a/ARF locus were performed
using procedures and probes as previously reported [9].
Statistical analysis
For comparisons of two groups, a t-test for indepen-
dent samples or non parametric Mann-Whitney U test
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Page 8 of 10were used. Correlations were computed by Pearson
correlational analysis. Statistical analysis and calcula-
tion of the regression coefficients were performed
using StatView software (SAS Institute Inc., Cary NC,
USA).
For calculating the acute cytotoxicity and the clono-
genic index, we first assigned for every cell line a rank-
ing value for each of the administered drugs. One was
the value assigned to the most sensitive and 18 to the
most resilient, with 2 to 17 being all the other inter-
mediate values. The six values obtained from each cell
line in either assay were added together, and the new
values thus obtained were used as basis for the final
ranking of the cell lines. For ease of evaluation of the
results, these values (acute cytotoxicity index and clono-
genic index) were changed into the values from 1 to 18.
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